{"id":"W2999047517","doi":"10.1016/j.clgc.2019.12.019","title":"Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Janssen Pharmaceuticals; Bristol-Myers Squibb Canada; EMD Serono; Ipsen; Ferring Pharmaceuticals; Sanofi Genzyme; Merck Sharp and Dohme; Ferring; AstraZeneca; Invitae; Innocrin Pharmaceuticals; Astellas Pharma US; Flatiron Health; Dendreon Pharmaceuticals; Bayer Fund; Astellas Pharma Canada; F. Hoffmann-La Roche; Exelixis; Sanofi; Celgene; Novartis; Merck; Roche; American Association for Cancer Research; Amgen; Janssen Biotech; Johnson and Johnson; AcelRx Pharmaceuticals; Myovant Sciences; Pfizer; Bristol-Myers Squibb; Bayer; Calithera Biosciences; Constellation Energy Group","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Docetaxel; Prednisone; Abiraterone acetate; Internal medicine; Oncology; Confidence interval; Abiraterone; Clinical trial; Androgen deprivation therapy; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001360027,0.0001492353,0.0003438768,0.00123755,0.0004793239,0.0009329289,0.0004980538,0.0004116629,0.001098717],"category_scores_gemma":[0.006150758,0.0002556771,0.0003143211,0.002991494,0.0004720945,0.0007669692,0.0007069919,0.00058371,0.0001645666],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001377839,"about_ca_system_score_gemma":0.00127737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01797371,"about_ca_topic_score_gemma":0.02723456,"domain_scores_codex":[0.9979145,0.0006503621,0.0004215168,0.0004914849,0.0003459739,0.0001762165],"domain_scores_gemma":[0.9914693,0.001051528,0.006021447,0.0002665829,0.0005379642,0.0006530682],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00004230005,0.00003242633,0.9984815,0.00001918714,0.000041851,0.00004257079,0.0001097941,0.0000428841,0.00002506341,0.00001912971,0.0002205177,0.0009227558],"study_design_scores_gemma":[0.00001730512,0.00008747175,0.9977632,0.00003613654,0.00002493753,0.0003463678,0.0007626578,0.0003737902,0.00004100454,0.00004570157,0.0004918638,0.000009575514],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963133,0.0008147964,0.0001486148,0.0003443167,0.00000805407,0.00003104518,0.001869994,0.000007062866,0.0004628046],"genre_scores_gemma":[0.9981136,0.000286769,0.0001805563,0.0001541303,0.00001157341,0.00002641468,0.001162971,0.000002625742,0.00006131023],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01797371,"threshold_uncertainty_score":0.03573823,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.103478777189982,"score_gpt":0.4589470104597338,"score_spread":0.3554682332697519,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}